Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03948035
Recruitment Status : Recruiting
First Posted : May 13, 2019
Last Update Posted : May 20, 2019
Sponsor:
Collaborator:
ClinAssess GmbH
Information provided by (Responsible Party):
Wuerzburg University Hospital

Brief Summary:

Of the next-generation compounds, the monoclonal antibodies (moAbs) have recently attracted a lot of interest in MM. The anti-SLAMF7 directed moAb elotuzumab has completed phase III trials in MM patients. One phase III trial in MM patients with one to three prior lines of therapy compared elotuzumab-Rd with standard Rd. The triple combination was shown to significantly prolong PFS in this patient cohort with a greater proportion of patients in at least very good partial response (VGPR) when compared to subjects on Rd. Notably, the rate of infusion-related reactions with this specific moAb was very low, with an overall rate of 10% in premedicated patients and only 1% of Grade 3 severity. Grades 4/5 infusion-related reactions were absent and only 1% of patients on elotuzumab discontinued for infusion-related reactions. Of particular interest is the observation in this trial, that response and PFS were independent of cytogenetic high-risk features, i.e., deletion of chromosome 17p and translocation t(4;14). This effect distinguishes elotuzumab from most, if not all, other drug-based approaches.

The investigators assume that incorporating the moAb into the KRd triple induction regimen should result in an even higher rate of deep (negative for MRD in conjunction with at least very good partial response [VGPR] as defined by the International Myeloma Working Group [IMWG]) with these responses occurring independently of cytogenetic risk. Due to potential interference of elotuzumab with serum immune fixation, the investigators chose VGPR rather than complete response (CR) to exclude false-positive immunofixation results. Furthermore the investigators hypothesize that combining elotuzumab with lenalidomide should prolong PFS further.


Condition or disease Intervention/treatment Phase
Newly Diagnosed Multiple Myeloma Drug: Elotuzumab Drug: Carfilzomib Drug: Lenalidomide Drug: Dexamethasone Other: autologous stem cell transplant Phase 3

  Show Detailed Description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 576 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd Prior to and Following Auto-SCT in Newly Diagnosed Multipe Myeloma and Subsequent Maintenance With Elotuzumab and Lenalidomide Versus Single-Agent Lenalidomide- A Phase III Study by DSMM
Actual Study Start Date : August 28, 2018
Estimated Primary Completion Date : August 2029
Estimated Study Completion Date : August 2029


Arm Intervention/treatment
Experimental: E-KRd/ Arm A
Induction/ Consolidation: Elotuzumab, Carfilzomib, Lenalidomide, Dexamethasone (E-KRd), autologous stem cell transplant, Maintenance: Elotuzumab, Lenalidomide
Drug: Elotuzumab
i.v. infusion. Induction 6 cycles: 10mg/kg BW D1,8,15,22 of cycle 1 and 2, D1,15 of cycles 3-6. Consolidation 4 cycles: 10mg/kg BW D1,15 of cycle 1-4. Maintenance 28-day cycles: 20mg/kg BW D1 of each 28-day cycle.
Other Name: Empliciti®

Drug: Carfilzomib
i.v. infusion. Induction 6 cycles: 20 mg/m² on D1 and 2 of cycle 1, 36 mg/m² on D8, 9, 15, 16 of cycle 1, 36 mg/m² on D1,2,8,9,15,16 of cycle 2-6; Consolidation 4 cycles: 36 mg/m² on days 1, 2, 8, 9, 15, 16 of cycles 1-4.
Other Name: Kyprolis®

Drug: Lenalidomide
hard capsule for oral use. Induction 6 cycles: 25mg D1-21 of cycle 1-6. Consolidation 4 cycles: 15mg D1-21 of cycle 1, 25mg D1-21 ov cycle 2-4. Maintenance 28-day cycles: 10mg D1-28 of cycle 1,2,3, 15mg D1-28 of cycle 4 and all subsequent cycles.
Other Name: Revlimid®

Drug: Dexamethasone
orally and i.v. IN ARM A:Induction 6 cycles: 28mg p.o. and 8mg i.v. D1,8,15,22 of cycles 1-2 and D1,15 of cycles 3-6, 40mg p.o. D8,22 of cycle 3-6. Consolidation 4 cycles: 28mg p.o. and 8mg i.v. D1,15 of cycle 1-4 and 20mg p.o. D8,22 of cycle 1-4. IN ARM B: Induction 6 cycles: 40mg p.o. D1,8,15,22 of cycles 1-6. Consolidation 4 cycles: 20mg p.o. D1,8,15, 22 of cycle 1-4 .
Other Name: Fortecortin®

Other: autologous stem cell transplant
autologous stem cell transplant

Active Comparator: KRd/ Arm B
Induction/ Consolidation: Carfilzomib, Lenalidomide, Dexamethasone (KRd), autologous stem cell transplant, Maintenance: Lenalidomide
Drug: Carfilzomib
i.v. infusion. Induction 6 cycles: 20 mg/m² on D1 and 2 of cycle 1, 36 mg/m² on D8, 9, 15, 16 of cycle 1, 36 mg/m² on D1,2,8,9,15,16 of cycle 2-6; Consolidation 4 cycles: 36 mg/m² on days 1, 2, 8, 9, 15, 16 of cycles 1-4.
Other Name: Kyprolis®

Drug: Lenalidomide
hard capsule for oral use. Induction 6 cycles: 25mg D1-21 of cycle 1-6. Consolidation 4 cycles: 15mg D1-21 of cycle 1, 25mg D1-21 ov cycle 2-4. Maintenance 28-day cycles: 10mg D1-28 of cycle 1,2,3, 15mg D1-28 of cycle 4 and all subsequent cycles.
Other Name: Revlimid®

Drug: Dexamethasone
orally and i.v. IN ARM A:Induction 6 cycles: 28mg p.o. and 8mg i.v. D1,8,15,22 of cycles 1-2 and D1,15 of cycles 3-6, 40mg p.o. D8,22 of cycle 3-6. Consolidation 4 cycles: 28mg p.o. and 8mg i.v. D1,15 of cycle 1-4 and 20mg p.o. D8,22 of cycle 1-4. IN ARM B: Induction 6 cycles: 40mg p.o. D1,8,15,22 of cycles 1-6. Consolidation 4 cycles: 20mg p.o. D1,8,15, 22 of cycle 1-4 .
Other Name: Fortecortin®

Other: autologous stem cell transplant
autologous stem cell transplant




Primary Outcome Measures :
  1. Induction phase [ Time Frame: At the end of Cycle 6 (168 days for all cycles plus up to 36 days) ]
    MRD negativity rate (%) as assessed by flow-cytometry in patients with VGPR or better response according to IMWG criteria following six cycles of induction treatment.

  2. Maintenance phase [ Time Frame: 3 years from randomisation ]
    Determination of progression-free survival (PFS) following randomisation


Secondary Outcome Measures :
  1. Measurement of long-term efficacy (1) [ Time Frame: 10 years ]
    Overall response rate (%) to treatment

  2. Measurement of long-term efficacy (2) [ Time Frame: 10 years ]
    Overall survival (months)

  3. Measurement of long-term efficacy (3) [ Time Frame: 10 years ]
    Quality of Life (Units on Scale; Unit range from 0 to 100; Units calculated via linear transformation of raw score (RS) values from scale with single-item measure from 1 to 7 on EORTC QLQ-C30 questionnaire equivalent; Formular for transformation: Unit = {(RS-1)/6}x100)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Eligible for autologous stem cell transplantation (ASCT)
  • Patient must not have been previously treated with any prior systemic therapy for the treatment of multiple myeloma (only dexamethasone at a cumulative dose of 320 mg; plasmapheresis/dialysis without concomitant chemotherapy,local irradiation of bone lesions; and surgical intervention permitted as pretreatment)
  • Newly diagnosed multiple myeloma according to the IMWG updated criteria42: Clonal bone marrow plasma cells ≥ 10% or biopsy proven bony or extramedullary plasmacytoma and any one or more of the following myeloma defining events:
  • Evidence of end organ damage that can be attributed to the underlying plasma cell proliferative disorder, specifically:

    • Hypercalcaemia: serum calcium > 0.25 mmol/L (> 1 mg/dL) higher than the upper limit of normal or > 2.75 mmol/L (> 11 mg/dL)
    • Renal insufficiency: creatinine clearance < 40 mL per min or serum creatinine > 177 μmol/L (> 2 mg/dL)
    • Anaemia: haemoglobin value of > 2 g/dL below the lower limit of normal, or a haemoglobin value < 10 g/dL
    • Bone lesions: one or more osteolytic lesions on skeletal radiography,computed tomography (CT), or PET-CT
  • Any one or more of the following markers of malignancy:

    • Clonal bone marrow plasma cell percentage ≥ 60%
    • Involved: uninvolved serum free light chain ratio ≥ 100, provided the absolute level of the involved light chain is at least 100 mg/L
    • One or more focal lesions of at least 5mm or greater in size on MRI studies
  • Measurable disease parameters as follows:
  • Serum monoclonal paraprotein (M-component) level ≥ 1 g/dL and/or urine M-protein level ≥ 200 mg/24 hours or
  • In case of IgA myeloma: Serum monoclonal paraprotein level ≥ 0.5 g/dL and/or urine M-protein level ≥ 200 mg/24 hours or
  • For patients with no detectable M-component: Serum FLC Assay: Involved FLC level ≥ 10 mg/dL (≥ 100 mg/L) provided serum FLC ratio is abnormal
  • ECOG Performance Status ≤ 2
  • Laboratory test results within these ranges:
  • White blood cell count ≥ 2 x 109/L
  • Absolute neutrophil (ANC) count ≥ 1.0 x 109/L
  • Platelet count ≥ 75 x 109/L
  • Haemoglobin > 8 g/dL
  • Calculated creatinine clearance (according to MDRD) ≥ 30 mL/minute
  • Total bilirubin ≤ 1.5 x upper limit of normal (ULN)
  • AST and ALT ≤ 2.5 x ULN
  • Corrected serum calcium level < 3.5 mmol/L (< 14 mg/dL)
  • Patient's legal capacity to consent to study participation
  • Patients capable to understand the purposes and risks of the study, who are willing and able to participate in the study and from whom written and dated informed consent to participate in the study has been obtained.
  • All females

    • must acknowledge to have understood the hazards lenalidomide can cause to an unborn fetus and the necessary precautions associated with the use of lenalidomide.
    • must use adequate contraception and agree to use two reliable forms of contraception simultaneously or to practice complete abstinence
    • must agree to have medically supervised pregnancy tests on a regular basis
    • must agree to abstain from breastfeeding while taking lenalidomide, carfilzomib and elotuzumab and for at least 28 days after the last dose of lenalidomide, carfilzomib, and elotuzumab.
  • Male subjects must

    • practice complete abstinence or use a condom during sexual contact with a pregnant female or a female with child bearing potential while taking lenalidomide, carfilzomib, and elotuzumab.
    • not donate semen or sperm
  • All subjects must

    • agree to abstain from donating blood while taking lenalidomide, during dose interruptions and for at least 28 days after the last dose of lenalidomide.
    • agree never to give lenalidomide to another person.
    • agree to return all unused lenalidomide capsules to the investigator (with exception of prescribed lenalidomide capsules)
    • be aware that no more than a 28-day lenalidomide supply may be dispensed with each cycle of lenalidomide during induction and consolidation therapy and be prescribed during maintenance therapy.

Exclusion Criteria:

  • POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy,
  • monoclonal protein, and skin changes)
  • Waldenström's macroglobulinemia or IgM myeloma
  • Plasma cell leukemia (> 2.0 x 109/L circulating plasma cells by standard differential blood count)
  • Pregnant, breast-feeding females, FCBPs and males who are unwilling to comply with the lenalidomide Pregnancy Prevention Risk Management Plan.
  • Patients with high cardiovascular risk, including but not limited to history of myocardial infarction or coronary stenting in the past 6 months; NYHA Class III or IV heart failure, uncontrolled angina, uncontrolled hypertension, severe uncontrolled arrhythmias
  • Prior cerebral vascular accident (CVA) with persistent neurological deficit
  • Active infection
  • Known HIV-seropositivity, active or chronic hepatitis A, B, C or D-infection (including patients who are tested anti-HBC positive and/or HBsAg positive).
  • Any other severe concomitant disease or disorder, including the presence of laboratory abnormalities, which places the subject at unacceptable risk or which could influence patient's ability to participate in the study and his/her safety during the study or interfere with interpretation of study results.
  • Greater or equal to Grade 2 peripheral neuropathy on clinical examination within 14 days before enrollment
  • Major surgery within 4 weeks prior to randomization
  • Any systemic anti-myeloma therapy within 4 weeks of randomization except a max. cumulative dose of 320 mg auf dexamethasone.
  • Any prior or concurrent malignancy other than multiple myeloma.
  • Exceptions include patients who have been disease-free for at least five years before study entry or patients with adequately treated and completely resected basal cell or squamous cell skin cancer, in situ cervical, breast or prostate cancer.
  • Known hypersensitivity to carfilzomib, lenalidomide, and elotuzumab or to any of the excipients of carfilzomib, lenalidomide, and elotuzumab or to any other component of any study drug formulation
  • Participation in any other clinical trial or treatment with any experimental drug or other experimental therapy within 28 days before enrolment to the study or during study participation until the end of treatment visit

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03948035


Contacts
Layout table for location contacts
Contact: Hermann Einsele, MD +49 (0)931 201 ext 40001 Einsele_H@ukw.de
Contact: Stefan Knop, MD +49 (0)931 201 ext 40013 Knop_S@ukw.de

Locations
Layout table for location information
Germany
Universitätsklinikum Würzburg, Medizinische Klinik II Recruiting
Wuerzburg, Bavaria, Germany, 97080
Contact: Stefan Knop, MD    +49 (0)931 201 ext 40013    Knop_S@ukw.de   
Sponsors and Collaborators
Wuerzburg University Hospital
ClinAssess GmbH
Investigators
Layout table for investigator information
Principal Investigator: Stefan Knop, MD Wuezburg University Hospital

Layout table for additonal information
Responsible Party: Wuerzburg University Hospital
ClinicalTrials.gov Identifier: NCT03948035     History of Changes
Other Study ID Numbers: DSMM XVII
2017-001616-11 ( EudraCT Number )
First Posted: May 13, 2019    Key Record Dates
Last Update Posted: May 20, 2019
Last Verified: May 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Wuerzburg University Hospital:
multiple myeloma
autologous stem cell transplant
Elotuzumab
Carfilzomib
Lenalidomide
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Dexamethasone
Dexamethasone acetate
Lenalidomide
Elotuzumab
BB 1101
Anti-Inflammatory Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents